Jan 12, 2026 09:10AM
Jan 12, 2026 09:10AM
Dec 30, 2025 09:20AM
Dec 30, 2025 09:20AM
Dec 23, 2025 09:29AM
Dec 23, 2025 09:29AM
Nov 12, 2025 09:11AM Lexaria extends pharmaceutical partnership agreement through April 2026
Nov 12, 2025 09:10AM
Oct 9, 2025 09:20AM
Oct 9, 2025 09:20AM
Sep 29, 2025 04:30PM
Sep 29, 2025 04:30PM
Sep 19, 2025 11:25AM
Sep 19, 2025 11:20AM Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain
Aug 27, 2025 09:20AM
Aug 14, 2025 09:20AM
Aug 14, 2025 09:20AM
Aug 6, 2025 09:20AM
Jul 28, 2025 09:25AM
Jul 28, 2025 09:25AM
Jul 23, 2025 09:28AM Lexaria claims technology could reduce GLP-1 drug side effects
Jul 23, 2025 09:25AM
Jun 23, 2025 09:15AM
Jun 23, 2025 09:15AM
Jun 11, 2025 09:05AM
Jun 11, 2025 09:05AM
Jun 5, 2025 09:20AM
Apr 28, 2025 04:15PM Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock
Apr 25, 2025 08:02AM
Apr 25, 2025 08:00AM
Apr 23, 2025 09:10AM
Apr 2, 2025 09:13AM
Apr 2, 2025 09:05AM
Mar 18, 2025 09:16AM
Mar 18, 2025 09:15AM Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)
Feb 27, 2025 08:00AM
Feb 24, 2025 08:02AM
Feb 24, 2025 08:00AM
Feb 20, 2025 08:04AM
Feb 20, 2025 08:00AM
Feb 11, 2025 08:03AM
Feb 11, 2025 08:00AM Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy
Feb 6, 2025 09:42AM
Feb 6, 2025 09:40AM
Jan 30, 2025 09:17AM
Jan 30, 2025 09:15AM
Jan 15, 2025 09:28AM
Jan 15, 2025 09:20AM
Jan 14, 2025 09:12AM Lexaria Bioscience's (LEXX) Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound
Jan 14, 2025 09:10AM

341,965 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All